Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Fresenius SE & Co. KGaA    FRE   DE0005785604

FRESENIUS SE & CO. KGAA

(FRE)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
11/14/2019 11/15/2019 11/18/2019 11/19/2019 11/20/2019 Date
47.72(c) 48.165(c) 48.39(c) 48.665(c) 48.385 Last
1 115 381 1 531 765 1 307 401 1 618 231 1 263 637 Volume
-0.55% +0.93% +0.47% +0.57% -0.58% Change
More quotes
Financials (EUR)
Sales 2019 35 351 M
EBIT 2019 4 572 M
Net income 2019 1 825 M
Debt 2019 16 040 M
Yield 2019 1,67%
Sales 2020 37 257 M
EBIT 2020 4 929 M
Net income 2020 1 990 M
Debt 2020 17 773 M
Yield 2020 1,75%
P/E ratio 2019 14,5x
P/E ratio 2020 13,5x
EV / Sales2019 1,22x
EV / Sales2020 1,20x
Capitalization 27 117 M
More Financials
Company
Fresenius specializes in designing, producing, and selling medical drugs, equipment, and devices used in clinical hospitalization and at home. Net sales break down by activity as follows: - dialysis treatment (49%; Fresenius Medical Care): sales of equipment for hemodialysis, pediatric dialysis,... 
More about the company
Surperformance© ratings of Fresenius SE & Co. KGaA
Trading Rating : Investor Rating :
More Ratings
Latest news on FRESENIUS SE & CO. KGAA
11/15Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations..
AQ
11/11FRES &C : Fresenius Kabi AG - Omega-3 fatty-acid enriched parenteral nutrition i..
AQ
11/06International companies to host live webcasts at Deutsche Bank's Depositary R..
AQ
11/05FRESENIUS : Vamed wins awards for spa and wellness facilities
PU
11/04FRESENIUS : Helios acquires medical diagnostics provider in Colombia
PU
11/04FRESENIUS : Buys Colombia's CediMed in EUR40 Million Investment
DJ
11/01FRESENIUS : Medical Care North America achieves strongest quality ratings to dat..
PU
10/31FRESENIUS SE & CO. KGAA : Release according to Article 41 of the WpHG [the Germa..
EQ
10/30FRESENIUS SE & CO. KGAA : Preliminary announcement of the publication of quarter..
EQ
10/29EUROPE : European shares break six-day winning streak, focus moves to Fed
RE
10/29GLOBAL MARKETS LIVE : Mastercard, Alphabet, Pfizer, LVMH…
10/29Global Stocks Slip as Investors Look Ahead to Earnings
DJ
10/29FRESENIUS MEDICAL CARE : beats third-quarter forecasts with strong sales of home..
RE
10/29FRESENIUS : Medical Care again delivers strong organic growth in the third quart..
PU
10/29FRESENIUS : 3Q Net Profit, Sales Grew; Backs Outlook
DJ
More news
News in other languages on FRESENIUS SE & CO. KGAA
11/18Francfort freinée par le commerce et Volkswagen (Dax:-0,26%)
11/18FRANKFURT STOCK EXCHANGE : Francfort stable (-0,03%), toujours attentive sur le ..
11/05FRESENIUS : Vamed erhält Auszeichnungen im Bereich Gesundheitstourismus
11/04Santhera ernennt Dario Eklund zum neuen CEO
11/04DPA-AFX-ÜBERBLICK : UNTERNEHMEN vom 04.11.2019 - 15.15 Uhr
More news
Analyst Recommendations on FRESENIUS SE & CO. KGAA
More recommendations
Stock Trading Strategies
FRESENIUS - 02/04
A trend reversal is in sight
BUY
More Stock Trading Analysis
Sector news : Hospitals, Clinics & Primary Care Services
11/18SOUTHEAST ASIA STOCKS : Singapore, Thailand rise on stimulus hopes; Philippines ..
RE
11/18IHH Healthcare Puts Offer for India's Fortis Healthcare on Hold
DJ
11/11UK building sector hit by surge in insurance costs after Grenfell fire
RE
11/06GLOBAL MARKETS LIVE : Xerox, T-Mobile, Sprint, IBM…
11/06CVS HEALTH : Beats Revenue Expectations, Raises Earnings Outlook
DJ
More sector news : Hospitals, Clinics & Primary Care Services
Chart FRESENIUS SE & CO. KGAA
Duration : Period :
Fresenius SE & Co. KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FRESENIUS SE & CO. KGAA
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 55,99  €
Last Close Price 48,67  €
Spread / Highest target 53,7%
Spread / Average Target 15,0%
Spread / Lowest Target -33,3%
EPS Revisions
Managers
NameTitle
Stephan Sturm President & Chief Executive Officer
Gerd Krick Chairman-Supervisory Board
Rachel Clare Empey Chief Financial Officer
Niko Stumpfögger Deputy Chairman-Supervisory Board
Klaus-Peter Müller Member-Supervisory Board
Sector and Competitors